Cisplatinum's Role in Treating Neuroblastoma
Author Information
Author(s): L. Bettan-Renaud, F. de Vathaire, J. Benard, N. Morardet, N. Pauzie, S. Bayet, O. Hartmann, C. Parmentier
Primary Institution: Institut Gustave Roussy
Hypothesis
Cisplatinum can effectively eliminate neuroblastoma cells from bone marrow during autologous bone marrow transplantation.
Conclusion
Cisplatinum shows high tumoricidal properties and is effective in purging neuroblastoma from bone marrow.
Supporting Evidence
- Cisplatinum was shown to have a high therapeutic index in purging neuroblastoma cells.
- The IC50 values for neuroblastoma cell lines ranged from 0.4 to 0.8 µM.
- At a concentration of 10 µM, cisplatinum produced a total tumoricidal effect.
- More than 70% of GM-CFC and over 90% of CFU-F cells remained viable at the purging dose.
Takeaway
Cisplatinum can help get rid of bad cancer cells in the bone marrow while keeping the good cells safe.
Methodology
The study used clonogenic assays to measure the cytotoxic effects of cisplatinum on neuroblastoma cell lines and normal bone marrow progenitor cells.
Limitations
The study was conducted in vitro, and results may not fully translate to in vivo conditions.
Participant Demographics
Bone marrow samples were obtained from 10 healthy donors.
Statistical Information
P-Value
1.29
Confidence Interval
1.14-1.47
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website